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Background/aim: This study aimed to assess the inflammatory adverse reactions of vocal fold injection laryngoplasty with hyaluronic
acid.
Materials and methods: This study was a retrospective chart review of patients who underwent vocal fold injection augmentation with
HA injection from January 2005 to September 2016 in nine different institutions. Demographic data, indication for injection, injection
techniques, types of injection material, settings of procedure, and complications were reviewed. The types of complication, onset time,
and management of complications were also noted.
Results: In all, 467 patients were identified. The majority of patients had been injected under general anesthesia (n = 382, 84.7%).
For injection material, two different types of hyaluronic acid were used: hyaluronic acid alone or hyaluronic acid with dextranomer.
Complications occurred in nine patients (1.9%). The majority of complications were inflammatory reactions (n = 7, 1.47%). Main
symptoms were dysphonia and/or dyspnea with an onset of 0 h to 3 weeks after the hyaluronic acid injection. Three patients were
hospitalized, one of which was also intubated and observed in the intensive care unit for 24 h. Systemic steroids and antibiotics were the
main medical treatment in the majority of cases. There was no statistical difference in complication rates between patients who received
hyaluronic acid and those who received hyaluronic acid with dextranomer (P = 0.220).
Conclusion: Hyaluronic acid can be considered as a safe substance for the injection of vocal folds with a low risk of inflammatory
reaction.
Key words: Vocal fold injection, hyaluronic acid, hyaluronic acid with dextranomer, inflammatory reaction, vocal fold paralysis, sulcus
vocalis

1. Introduction
Glottic insufﬁciency is one of the most common etiologic
factors of dysphonia. Glottic insufﬁciency is usually
secondary to unilateral vocal fold paralysis, unilateral
or bilateral vocal fold paresis, sulcus vocalis, and
presbylaryngitis. Injection laryngoplasty is a common
therapeutic option for treatment of glottic insufficiency.

The purpose of injection is to gain adequate glottic closure
to alleviate phonatory and swallowing symptoms [1].
Although several injectable substances have been in use for
the larynx since the inception of injection laryngoplasty in
1911, the ideal one is yet to be found [2].
Hyaluronic acid (HA) is among the most commonly
used substances for injection laryngoplasty. Its ease of
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injection and unique properties in tissue regeneration,
namely recruitment of fibroblasts, deposition of collagen,
and improvement of the viscoelastic properties of the
injected tissues, have made it a popular injectable material
[3]. This naturally existing polysaccharide is found in the
extracellular matrix of human cells and is also abundant
in the vocal fold lamina propria. It is biocompatible and
rarely induces foreign body reactions or cell-mediated
immune responses. Clinical studies have supported the
safety and efficacy of HA for vocal fold augmentation [4].
HA has been demonstrated as a safe material for vocal
fold injection in the literature; however, most of these
studies have small sample sizes. There has been case reports
about inflammatory adverse reactions after vocal fold HA
injections [5–7]. Recently, a study with a large sample size
published the results from the assessment of 186 patients
from a single institution [8]. In our study we aim to gather
the clinical data of several institutions to understand the
presentation and management of inflammatory adverse
reactions of HA. The goal of our study is to identify the
rate of complications and the adverse reactions after HA
injection laryngoplasty in a multiinstitutional setting.
2. Materials and methods
A retrospective chart review of all patients from
nine institutions who underwent vocal fold injection
laryngoplasty with HA alone (Restylane, Galderma/Q‐
Med, Uppsala, Sweden) or HA with dextranomer (HA-D;
Dexell, Istem Medikal, Ankara, Turkey) from January 2005
to September 2016 was performed. Injections were done
either unilaterally or bilaterally in one session. The side
and volume of injectable materials were decided according
to clinical decision of the physician. A retrospective chart
review was performed to identify patients with local
complications. Patients with previous laryngeal surgery,
vocal fold injections and patients with radiated neck were
excluded from the study.
Demographic data, injection technique, type of
injection material, the indication for injection, location
of the procedure, and occurrence of complications were
reviewed. Type, onset, and management of complications
were also noted for patients with complications. Results
were grouped according to the location of the procedure:
under local anesthesia in the office setting (office group) or
under general anesthesia in the operating room via direct
microlaryngoscopy (OR group).
Complication rates were compared according to
injection materials and the technique of injection.
Statistical analysis of the study was performed using the
MedCalc Statistical Software version 12.7.7 (MedCalc
Software bvba, Ostend, Belgium). The differences between
groups were compared using the chi-squared test (or
Fisher’s exact test when applicable).
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3. Results
A total of 476 patients underwent laryngeal HA injection
over an 11-year period in nine institutions. The average
age of patients was 47.1 ± 13.7 years (range = 19–70), and
the only indications were vocal fold paralysis (n = 417) and
sulcus vocalis (n = 59). In all, 403 patients (84.6%) were
injected with HA-D, and 73 (15.4%) were injected with HA
only. The majority of injections were done under general
anesthesia (OR group) (n = 382, 84.7%).
Complications were seen in nine patients. The mean
age of patients with complications was 46.7 years (range =
36–57), and six of these patients were women. Five of the
patients who experienced complications were in the OR
group and received the injection under general anesthesia,
whereas the remaining four were in the office group. There
was no significant difference between complication rates
in the office group and those in the OR group (P = 0.08).
The main indication was unilateral vocal fold paralysis
(n = 7), whereas two of the patients had sulcus vocalis.
Although all the patients with complications were injected
with HA-D, there was no statistically significant difference
between patients who received HA and those who received
HA-D (P = 0.220).
Five patients with complications presented mainly
dyspnea, and the other four presented the chief complaint of
dysphonia. The symptoms were observed postoperatively
within the first 24 h in the majority of patients (n = 5).
However, it was observed postoperatively on the second
day in two patients, and on the third week in one patient.
In videolaryngostroboscopic examination, the most
common findings included hyperemia and edema of the
vocal folds with or without false vocal folds, which were
observed in seven patients, although the severity of these
inflammatory findings varied (n = 7). Arytenoids were
inflamed in five of these seven patients, and movements
of the vocal folds were impaired in three of them, although
their vocal folds were mobile preoperatively (Figures
1–3). In one patient, VLS examination revealed vocal fold
hematoma that decreased mucosal wave and amplitude
in one side of the larynx. In another patient, superficial
deposition of the injected material on the vocal fold were
noted, which also caused decreased mucosal wave and
irregular closure in the affected vocal fold (Table).
Six of the patients with local inflammatory reaction
received the treatments. Oral or parenteral corticosteroid
was used as the main treatment in every patient who
received treatment, and three of these patients received
additional antibiotic treatment. Four of the patients needed
1 or 2 days of hospitalization. Two of them were kept
under observation in the intensive care unit for 24 h; of
these two patients, one underwent orotracheal intubation.
All symptoms resolved between 2 days to 3 weeks in these
patients.
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Figure 1. Flexible laryngoscopy showing edema at the injection
site, left arytenoid (star), and aryepiglottic fold (arrow) of patient
1, one day after injection.

Figure 2. Laryngoscopic examination of patient 8 one day
after injection, demonstrating severe left vocal fold (star), left
aryepiglottic fold (black arrow), and left arytenoid edema (white
arrow).

Figure 3. Laryngoscopic examination of patient 8 three days
after injection with decreased edema in the larynx after 2-day
hospitalization.

Patients who demonstrated no signs of inflammation
received no acute treatment or hospitalization. The
patient with vocal fold hematoma was observed without
treatment, and the hematoma resolved spontaneously
in 2 weeks, completely preserving the integrity of
mucosal wave and amplitude. However, the patient with
superficial deposition of the injected material underwent
microlaryngoscopic surgery for removal of the deposit 3
months later.
In our patient series of 476 individuals, the overall
complication rate was 1.9%, (9/476), and the inflammatory
complication rate was 1.47% (7/476). There was no
difference in terms of inflammatory complication rates
between office (n = 3) and OR (n = 4) groups (P = 0.142).
Although all the inflammatory complications were only
seen in HA-D injected patients, there was no statistically
significant difference for these complications between
patients treated with HA and those treated with HA-D (P
= 0.309)
4. Discussion
HA is a commonly used material in injection laryngoplasty.
However, it only lasts approximately 3 to 6 months [4]. In
our patient series, two types of injection material were
used: HA and HA-D. HA with dextranomer aims to
increase the duration of the material with the permanence
of the positive load of dextranomer. This form of HA
is frequently used in urology for vesicoureteral reflux
treatment [9]. No known inflammatory side effect with
HA-D in urological practice has been documented in the
recent literature [9]. Oguz et al. demonstrated the safety
and efficacy of HA-D for laryngeal injections in a small
group of patients [10]. Similarly, in our series, there was no
significant difference for complication rates between HA
and HA-D.
Injection laryngoplasty has been a workhorse in
laryngology since it was ﬁrst described by Brunings [2].
During the last century, with the improvements in general
anesthetics, surgeons now prefer the operating room for
injections. However, in the last 20 years, there has been
a rising trend of in-office laryngeal injections [11]. The
safety of the office-based injection is widely accepted in
the literature [5,11]. In our study, only a small group of
patients were injected in the office (n = 69, 14.5%), and
four out of nine complications (44.4%) were experienced
by patients who received office-based injections. There
was no significant difference for overall complication
rates between office-based injections and operating room
injections in our series. Furthermore, for inflammatory
complications, there was also no difference between these
groups. Complication rates for injection laryngoplasty
are very low, and to claim definitive conclusions, larger
multiinstitutional studies are needed [5].
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Table. Clinic data of the patients with complications.
Case Age Sex Approach

Diagnosis Symptom

VLS Exam

Onset

Treatment

Interventions

1

50

M

Transoral
(GA)

UVFP

Dysphonia

Vocal fold edema
(Figure 1)

24 h

2

44

F

Transoral
(GA)

UVFP

Dysphonia Vocal fold edema

24 h

3

42

M

Transoral
(GA)

Sulcus
vocalis

Superior
Dysphonia transposition of
material

0h

Clinic
follow-up

90th day surgery 90 days

F

Transoral
(GA)

UVFP

Inflammation
Dysphonia edema in FVF,
arytenoid, and VF

24 h

Antibiotic
steroid

Intubation, ICU
(1 day)
3 days
Hospitalization
(totally 2 day)

3 weeks

Systemic
steroid

2 ED visit
1-night
hospitalization

3 weeks

0h

Systemic
steroid

2 days
hospitalization
(1-night ICU)

4 days

72 h

Oral steroid
and antibiotic

1 week

24 h

Systemic
steroid

2 days
hospitalization

2 day

0h

Clinic
follow-up

-

2 days

4

54

5

46

F

Thyrohyoid
(LA)

Sulcus
vocalis

Dyspnea

6

57

M

Transoral
(GA)

UVFP

Dyspnea

7

36

F

Thyrohyoid
(LA)

UVFP

Dyspnea

8

55

F

Transoral
(LA)

UVFP

Dyspnea

9

37

F

Cricothyroid
UVFP
(LA)

Dyspnea

Inflammation
and edema in
FVF, arytenoids,
decreased VF
motion
Bilateral
inflammation edema
in FVFs, arytenoids,
decreased VF
motion
Inflammation
edema in FVF,
arytenoid
Inflammation
edema in FVF,
arytenoid (Figures 2
and 3)
Hematoma

Clinic followup
Antibiotic
steroid
(inhaler)

Resolution
time
2 weeks
60 days

GA: general anesthesia, LA: local anesthesia, UVFP: unilateral vocal fold paralysis, ICU: intensive care unit, VF: vocal fold, FVF: false
vocal fold.

Complications that may be associated with vocal
fold HA injection can be divided into two main groups:
technical problems and inflammatory problems. Technical
problems are related to the applied volume, application
depth, and application area. Of the nine patients included
in our series, two of them (22%; cases 3 and 9) experienced
complications that could be considered as technical
problems, such as hematoma and submucosal injection.
Cases involving such technical problems have been
described in the literature [7,8].
Besides the technical problems mentioned above, seven
out of nine patients in our series experienced complications
that can be classified as inflammatory. In animal studies,
mild inflammation has been observed after vocal fold HA
injection; however, no necrosis or granuloma formation

822

has been observed [12]. In the literature, a few case series
and case reports have indicated inflammatory adverse
reactions following vocal fold HA injection [5–7]. In the
largest series published by Dominguez et al., the incidence
of inflammatory complications was 3.8%. In our patient
group, this rate was 1.47% [8].
The onset of inflammatory reaction after vocal fold
HA injection varies in the literature. Although in some
of the series, there were patients whose symptoms started
right after or several hours after injections [5,8], the
most common onset time was 2 or 3 days after injection
laryngoplasty in most of the series [7,8]. Very rarely, the
start of the symptoms could be delayed for up to 3 weeks.
Our results were similar with those recorded in the
literature.
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Various side effects associated with dermal HA
injection have been described in the literature. These
side effects include erythema, edema, and irritation to
foreign body granuloma formation, ulceration, necrosis,
and hypersensitivity reactions. The frequency of these
side effects ranges between 0.06% and 0.8% in dermal
applications [13,14]. HA may cause adverse inflammatory
reactions through three main mechanisms: an ischemic
event, an allergic or hypersensitivity reaction, or an acute
infection of bacterial origin that causes inflammation with
fluctuant and erythematous nodules [15].
Vasoconstriction may be one of the possible reasons
for injections in the larynx because of a region limitation
by cartilage from the lateral. In the case of overinjection,
especially after radiotherapy, compression may occur
in the vascular structures of the larynx, which may
lead to ischemia. HA injections that cause vascular
compression in dermal injections usually show an acute
whitening followed by regional necrosis and ulceration
in postoperative hours [13]. There is one report in the
literature of a suspected compartment syndrome of the
hemilarynx after injection with HA in a patient with a
history of radiation [16]. Although patient with a history
of neck radiotherapy was excluded in our study, there are
no complications in this patient subgroup in Dominguez
et al.’s series [8]. The injected volume of the material could
be a factor leading possible cause of vascular compression.
Unfortunately, there is data about the volume of the
augmentation in our series. Even though in Dominguez
study, the volume of injected materials in patients with
inflammatory complication is within the range of average
amount of injected HA, the relation between the amount
of the injected HA and the inflammatory complication is
not clearly understood yet.
Hypersensitivity due to bacterial proteins can be
observed in relation to the production technique. HAbased injectable material contains very small amounts
of protein, which can cause some reactivity. Currently,
purification of HA fillers is considered to be more
effective than before. However, the alleged reasons for
hypersensitivity are less consistent. HA fillers might still
contain trace amounts of protein contaminants even after
purification. Therefore, hypersensitivity is still the most
important pathophysiological cause [17].
In our patient series, HA-D was used for all patients
with inflammatory complications. Inflammatory
complication rates in our study were 1.9%. Although no
statistical difference was demonstrated between HA-D
and HA injections, it can be speculated that dextranomer
may be the trigger for hypersensitivity. Even though no
inflammatory side effects have been shown in the literature
from urological practice, because of the location of the
injection site, the possibility may be easily underestimated.

In the published clinical series by Dominquez et al., none
of the augmentations include dextranomer or any other
cationic substance. The inflammatory complication rate of
their study (3.8%) [8]. was also similar to ours. Another
case series of vocal fold HA injection demonstrated an
inflammatory complication rate of 4.7% over 62 injections
[18].
Infection is an important complication that must be
avoided in dermal HA injections. This kind of complication
is rare in dermal applications [16]. In patients with
infection, increased white-blood-cell (WBC) and Creactive protein (CRP), and/or abscess formation would
be expected. Treatment with antibiotics and hyperbaric
oxygen therapy after drainage has been demonstrated as
an effective treatment approach. In cultures after abscess
drainage, staphylococcal and streptococcal species were
detected most frequently in facial application of HA [14].
Although none of the patients with complications
exhibited WBC count elevation, empiric parenteral
antibiotic therapy was initiated in all individuals with
inflammatory findings in our patient group. This occurred
because a significant proportion of patients applied with
a disturbing complaint, such as dyspnea, and all possible
treatment options were provided empirically.
In the literature, only one case of laryngeal abscess
after vocal fold HA injection has been reported. In
that case, the patient had a high WBC count and
constitutional symptoms, and no organism was revealed
in the microbiological culture and gram stain from the
abscess sample. The patient’s symptoms were relieved after
drainage, systemic antibiotic, and corticosteroid therapy
[15].
The most commonly used treatment among our
patients was the corticosteroid. If it is accepted that
inflammatory complications happen as a result of
hypersensitivity reactions or infections, which are the most
likely pathophysiologic explanations, we can speculate
that corticosteroids may have been helpful in decreasing
edema and inflammation in our patients. Although
none of the patients in our study had higher WBC or
C-reactive protein, some of them also received empiric
antibiotic treatment. In the facial application of HA, when
a patient has an inflammatory reaction, antibiotics are
widely used with hyaluronidase and corticosteroids [14].
Hyaluronidase would be beneficial to decrease bulkiness
in overinjection complications; however, while working on
the glottic level, it would cause an acute reduction in the
size of the airway.
Surgery is also an option for patients with severe
dyspnea resulting from HA injection. Tracheotomy may be
needed in an advanced airway obstruction. In our series,
only one patient with bilateral injection was intubated and
hospitalized in intensive care for 1 day, but none of our
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patients had a tracheotomy performed. Only one patient
(case 3), who had transposition of injection material in the
vocal fold, received surgical intervention in our study.
Although medical treatment and surgery are possible
treatment options that can be offered for inflammatory
complications of vocal fold injection, none of these
treatments are evidence-based. Future studies are needed
to clarify special treatment modalities for inflammatory
complications of vocal fold injection.
To the best of our knowledge, our study is the largest
vocal fold HA injection series ever published. Dominguez
et al. published the results of 186 patients from a single
institution [8]. Gathering and assessing complications from
different institutions increases the possibility of identifying
appropriate approaches to these rare complications.
Multiinstitution retrospective studies have some
disadvantages as well. It is not easily possible to standardize
the treatment and management protocols. Each clinic has a
different method of archiving patients’ data. This can limit
the quality of information obtained from retrospective
studies such as ours. Patients’ perceptual and acoustic voice
analyses could be used in a prospective setting. Absence
of patient-centered questionnaires was also another
limitation of our study. These indices are widely used in
laryngology clinics. They are especially useful to observe
problems from patients’ perspective and to compare the
results of different institutes.

5. Conclusion
Injection laryngoplasty with HA is a common therapeutic
option for the treatment of glottic insufficiency. In our
series, complications of all types were found to occur at
a rate of 1.9%. Dyspnea and dysphonia were the common
symptoms of complication most commonly starting after
1 day. Corticosteroid and antibiotic are the most accepted
treatment by the authors of the study. HA can be considered
a safe substance for vocal fold injections.
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